Simple approaches to patient care are better — exceptwhen they are not. Recent clinical studies are leading to areexamination of the paradigm whereby efforts to prevent vasculardisease focus on the achievement of particular levels of riskfactors such as low-density lipoprotein (LDL) cholesterol, systolicblood pressure, and glycated hemoglobin. Although these factorsand their levels are important determinants of the developmentand progression of vascular disease, it is increasingly apparentthat the specific strategies used to modify them make a criticaldifference in patient outcomes. This insight has implicationsfor clinical practice, performance measurement, and regulatoryrequirements.
Dr. Krumholz is a professor of medicine at Yale University School of Medicine and director of the Center for Outcomes Research and Evaluation at Yale–New Haven Hospital — both in New Haven, CT. Dr. Lee is network president of Partners HealthCare System in Boston and an associate editor of the Journal.
This article (10.1056/NEJMp0803740) was published at www.nejm.org on June 6, 2008. It will appear in the June 12 issue of the Journal.
This article has been cited by other articles:
Potenza, M. A., Gagliardi, S., De Benedictis, L., Zigrino, A., Tiravanti, E., Colantuono, G., Federici, A., Lorusso, L., Benagiano, V., Quon, M. J., Montagnani, M.
(2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am. J. Physiol. Endocrinol. Metab.
297: E685-E694
[Abstract][Full Text]
Dhar, G. C.
(2009). Intensive glycemic control: Implications of the ACCORD, ADVANCE, and VADT trials for family physicians. cfp
55: 803-804
[Full Text]
The NICE-SUGAR Study Investigators,
(2009). Intensive versus Conventional Glucose Control in Critically Ill Patients. NEJM
360: 1283-1297
[Abstract][Full Text]
Kassabian, S. G.
(2009). Hemoglobin A1c Testing, Board-Recertification Scores, and Treatment Outcomes. Arch Intern Med
169: 417-417
[Full Text]